The year ahead for Life Sciences & Diagnostics

From recent Citi report:

Top Picks for 2015: ILMN and PKI — Buy-rated Illumina (ILMN) and PerkinElmer (PKI) are our top picks heading into 2015. ILMN should continue to benefit from a significant portfolio re-fresh that has been pointed towards an expanding $20+ billion market opportunity. We believe consumables pull-through on 2014 instrument placements will be strong, and expect to see meaningful progress towards furthering the penetration of the clinical markets. To this point, we see the rise of next-gen sequencing as a clinical genomics tool to be the best multi-year investment theme in life sciences. For PKI, macro factors will certainly be in play, but our bullish stance is driven by a growth and margin expansion opportunity that appears slightly above average, along with valuation that is slightly below average.